Status:
COMPLETED
A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Irritable Bowel Syndrome (IBS)
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients.
Eligibility Criteria
Inclusion
- \- Diagnosis of IBS which meets the Rome II criteria, screening pain score to be \> 1.5 (0= no pain, 4 = very severe pain)
Exclusion
- Subjects not meeting the Rome II criteria for the diagnosis of IBS
- Subjects with no stool for 7 days during the screen
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00394186
Start Date
August 1 2006
Last Update
May 18 2009
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Concord, New South Wales, Australia, 2139
2
GSK Investigational Site
Caboolture, Queensland, Australia, 4510
3
GSK Investigational Site
Kippa-Ring, Queensland, Australia, 4021
4
GSK Investigational Site
Spring Hill, Queensland, Australia, 4000